A Phase 2 Randomized Trial Evaluating the Antiviral Activity and Safety of the Direct-Acting Antiviral Bemnifosbuvir in Ambulatory Patients with Mild or Moderate COVID-19 (MOONSONG Study)-Reference-Cited by-同舟云学术

A Phase 2 Randomized Trial Evaluating the Antiviral Activity and Safety of the Direct-Acting Antiviral Bemnifosbuvir in Ambulatory Patients with Mild or Moderate COVID-19 (MOONSONG Study)

Published:2023-08-17 Issue:4 Volume:11 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Boffito Marta¹²,Dolan Eamon³,Singh Karishma⁴,Holmes William⁵,Wildum Steffen⁶,Horga Arantxa⁷,Pietropaolo Keith⁷,Zhou Xiao-Jian⁷,Clinch Barry⁵,Collinson Neil⁵,Ukachukwu Vincent⁵^ORCID

Affiliation:

1. Chelsea and Westminster Hospital NHS Foundation Trust London, United Kingdom

2. Imperial College London, London, United Kingdom

3. Connolly Hospital, Dublin, Ireland

4. Tower Family Healthcare, Bury, United Kingdom

5. Roche Products Ltd., Welwyn Garden City, United Kingdom

6. Roche Pharma, Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland

7. Atea Pharmaceuticals, Boston, Massachusetts, USA

Abstract

COVID-19 continues to be a major global public health challenge, and there remains a need for effective and convenient direct-acting antivirals that can be administered outside health care settings. Bemnifosbuvir is an oral antiviral with a dual mechanism of action and potent in vitro activity against SARS-CoV-2.

Funder

F. Hoffmann-La Roche Ltd

Atea Pharmaceuticals

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.00077-23

Reference35 articles.

1. Johns Hopkins University. 2022. COVID-19 dashboard. https://coronavirus.jhu.edu/map.html. Accessed 3 October 2022.

2. Associations Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants and Risk of Coronavirus Disease 2019 (COVID-19) Hospitalization Among Confirmed Cases in Washington State: A Retrospective Cohort Study

3. Epidemiology of SARS-CoV-2

4. Centers for Disease Control and Prevention. 2022. Symptoms of COVID-19. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html. Accessed 3 October 2022.

5. European Medicines Agency. COVID-19 vaccines: key facts. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-key-facts. Accessed 3 October 2021.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Human bronchopulmonary disposition and plasma pharmacokinetics of oral bemnifosbuvir (AT-527), an experimental guanosine nucleotide prodrug for COVID-19;Journal of Antimicrobial Chemotherapy;2024-05-06

2. Ritonavir: 25 Years’ Experience of Concomitant Medication Management. A Narrative Review;Infectious Diseases and Therapy;2024-04-12

3. Shaping the future of antiviral Treatment: Spotlight on Nucleobase-Containing drugs and their revolutionary impact;Bioorganic Chemistry;2024-03

4. Docking and other computing tools in drug design against SARS-CoV-2;SAR and QSAR in Environmental Research;2024-02